Johnson John
Director at XERS; Director at AXGN; Chief Executive Officer at CEMPRA, INC., and 1 more
- Sold, on record
- $3.9M
- Dollars the filings state
- Form 4 sales
- 8
- Latest Jun 4, 2026
- Form 144 notices
- 6
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- XERSXeris Biopharma Holdings, Inc.Director
- AXGNAxogen, Inc.Director
- CEMPRA, INC.Chief Executive Officer
- SAVIENT PHARMACEUTICALS INCChief Executive Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- XERS257,900 shares
- AXGN60,502 shares
- SAVIENT PHARMACEUTICALS INC17,650 shares
- CEMPRA, INC.13,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 144 notice AXGNNoticeDec 9, 2025 2025
Filed to sell 21,686 shares ($650k)
Johnson John, Director
No 10b5-1 planFiling
- 2 Form 4 sale AXGNUnusualDec 9, 2025 same day
Sold 45,379 shares at $30.64 ($1.4M)
Johnson John, Director
No 10b5-1 planSold 100% of holdings ($1.4M position)0 shares leftFollows a Form 144Filing
- 3 Form 4 sale XERSNo planDec 19, 2025 +10 days
Sold 135,400 shares at $7.22 ($978k)
Johnson John, Director
No 10b5-1 planSold 16.2% of holdings ($6M position)698,083 shares leftFollows a Form 144Filing
- 4 Form 144 notice XERSNoticeDec 19, 2025 same day
Filed to sell 135,402 shares ($977k)
Johnson John, Director
No 10b5-1 planFiling
- 5 Form 144 notice AXGNNoticeMay 7, 2026 +139 days
Filed to sell 11,050 shares ($478k)
Johnson John, Director
No 10b5-1 planFiling
- 6 Form 4 sale AXGNUnusualMay 7, 2026 same day
Sold 11,050 shares at $43.26 ($478k)
Johnson John, Director
No 10b5-1 planSold 100% of holdings ($478k position)0 shares leftFollows a Form 144Filing
- 7 Form 144 notice XERSNoticeJun 4, 2026 +28 days
Filed to sell 15,000 shares ($88k)
Johnson John, Director
10b5-1 planFiling
- 8 Form 4 sale XERSRoutineJun 4, 2026 same day
Sold 15,000 shares at $6.09 ($91k)
Johnson John, Director
10b5-1 planSold 2.1% of holdings ($4.3M position)683,083 shares leftFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (14)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jun 5, 2026 | XERS | Director | Form 4 sale | 15,000 | $91k | 2.1% | Routine | SEC |
| Jun 4, 2026 | Jun 4, 2026 | XERS | Director | Form 144 notice | 15,000 | $88k | Notice | SEC | |
| May 7, 2026 | May 8, 2026 | AXGN | Director | Form 4 sale | 11,050 | $478k | 100.0% | Unusual | SEC |
| May 7, 2026 | May 7, 2026 | AXGN | Director | Form 144 notice | 11,050 | $478k | Notice | SEC | |
| Dec 19, 2025 | Dec 19, 2025 | XERS | Director | Form 144 notice | 135,402 | $977k | Notice | SEC | |
| Dec 19, 2025 | Dec 19, 2025 | XERS | Director | Form 4 sale | 135,400 | $978k | 16.2% | No plan | SEC |
| Dec 9, 2025 | Dec 10, 2025 | AXGN | Director | Form 4 sale | 45,379 | $1.4M | 100.0% | Unusual | SEC |
| Dec 9, 2025 | Dec 9, 2025 | AXGN | Director | Form 144 notice | 21,686 | $650k | Notice | SEC | |
| Dec 8, 2025 | Dec 8, 2025 | AXGN | Director | Form 144 notice | 23,693 | $740k | Notice | SEC | |
| Aug 13, 2025 | Aug 15, 2025 | XERS | Director | Form 4 sale | 107,500 | $787k | 11.4% | No plan | SEC |
| Aug 13, 2025 | Aug 13, 2025 | XERS | Director | Form 144 notice | 107,500 | $786k | Notice | SEC | |
| Jun 9, 2025 | Jun 11, 2025 | AXGN | Director | Form 4 sale | 4,073 | $43k | 14.0% | No plan | SEC |
| Jun 27, 2019 | Jul 2, 2019 | CEMPRA, INC. | Chief Executive Officer | Form 4 sale | 13,000 | $72k | 25.8% | Unusual | SEC |
| Jan 3, 2012 | Jan 4, 2012 | SAVIENT PHARMACEUTICALS INC | Chief Executive Officer | Form 4 sale | 17,650 | $41k | 6.5% | Plan not stated | SEC |